By exploiting the role of CK2 in GBM and its related signaling pathways (PI3K/Akt, JAK/STAT, and proliferation pathway, as well as regulation of NFs signaling), which contribute to tumorigenesis, these data allowed us to recognize in CX-4945 a promising agent in counteracting GBM. The gene discussed is SOAT1; the disease is glioblastoma.